Skip to content

Inspection prep notes · Supply, manufacturing and packaging

Supplier qualification and certificates of analysis

Also called: supplier qualification, vendor qualification, certificate of analysis, COA

FDA looks less at whether a supplier's certificate of analysis is on file than at whether the firm has confirmed for itself that the certificate can be relied on. The findings below are quoted from warning letters and FDA 483s.

What inspectors cited

1Incoming components were not tested for identity

You failed to perform adequate identity testing of incoming components used in the manufacture of your OTC drug products.

FDA Warning Letter · SnugZ USA, Inc. · 2026-10-20 · View document

Specific identification tests are not conducted on components that have been accepted based on the supplier's report of analysis.

FDA 483 · Tripak Pharmaceuticals Pty Ltd. · 2026-11-13 · View document

2There was no sound basis for verifying the reliability of supplier certificates of analysis

You also relied on your suppliers' certificates of analysis (COA) for (b)(4) without demonstrating the reliability of your suppliers' test analyses at appropriate intervals.

FDA Warning Letter · Guangdong Bangze Medicine Co., Ltd. · 2026-11-03 · View document

Your written procedure for supplier qualification process, SOP GMP-SOP-S-017, revision 2 on Purchasing / subcontractor management procedure manual is deficient and does not specify the number of batches required to be tested for verification of vendor COA during vendor qualification of raw materials.

FDA 483 · Sumitomo Osaka Cement Co., Ltd · 2026-11-05 · View document

3Components at high risk of DEG and EG contamination were not adequately tested for identity

You failed to adequately test your incoming components at high risk of DEG and EG contamination for identity before using them to manufacture your drug products.

FDA Warning Letter · RNA Bio/Pharma, Incorporated · 2025-11-18

For example, you failed to adequately test each shipment of each lot of glycerin and propylene glycol for identity, components at higher risk for diethylene glycol (DEG) and ethylene glycol (EG) contamination.

FDA Warning Letter · Creative Essences, Inc. · 2025-10-07 · View document

4Suppliers were not assessed and qualified

Based on the records and information you provided, your quality unit (QU) failed to adequately qualify your suppliers of critical raw materials for the manufacturing of (b)(4) API at your facility.

FDA Warning Letter · Nanjing Hanxin Pharmaceutical Technology Co. Ltd. · 2026-11-10

Your firm has not established and maintained a program to ensure the reliability of the supplier's capabilities through appropriate assessment and testing procedures.

FDA 483 · Conroe Welding Supply, Inc · 2026-10-23 · View document

5Containers and closures from suppliers were not verified by the firm's own testing

Specifically, your firm has not conducted at least one specific identity test and has not established the reliability of the suppliers analyses through appropriate validation of the supplier's test result at appropriate intervals for [redacted] vial used as primary container for Adstiladrin drug product.

FDA 483 · FinVector Oy · 2026-10-20 · View document

Sterility of critical product-contact equipment sterilized by external vendors (i.e., sterile Starclick specimen final container closure system, tissue slicer, is not being verified through periodic sampling of incoming lots.

FDA 483 · Duke University · 2026-10-30 · View document

Questions to check against your procedures

  1. Is every incoming component tested for identity?
  2. Where you rely on a supplier's certificate of analysis, do you confirm the reliability of the supplier's analyses at appropriate intervals?
  3. Does your procedure specify how many batches are tested when verifying a supplier's certificate of analysis?
  4. Is each shipment of components at high risk of DEG and EG contamination, such as glycerin and propylene glycol, tested for identity?
  5. Is there a program to assess and qualify suppliers of critical raw materials?
  6. Are containers, closures and items sterilized by outside vendors also verified by your own testing or periodic sampling?

Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-16.

Weekly Newsletter

New GMP inspection findings, every Monday

Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.